by Claudia Li | Feb 27, 2024 | Press Releases
Press release DiaCarta, Inc. and OncoAssure Ltd. Collaborate to Launch Prostate Cancer Lab Developed Test FollowFollow DiaCarta, Inc. (“DiaCarta”), a pioneer in molecular diagnostic test development for cancer and infectious diseases, today announced that...
by Admin | Feb 20, 2024 | Press Releases
Press release DiaCarta’s RadTox™ Test to Monitor Tumor Response Receives Medicare Coverage FollowFollow DiaCarta, a leading molecular diagnostics company personalizing patient care through liquid biopsy, proudly announced that its revolutionary RadTox™ test,...
by Admin | Feb 14, 2024 | Blog
Who should be tested for VEXAS syndrome? FollowFollow As a relatively newly discovered autoinflammatory disease, VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is associated with mutations in the UBA1 gene. Diagnosis of the disease relies on...
by Admin | Feb 6, 2024 | Blog
Genetic Testing for the VEXAS Syndrome FollowFollow Diagnosis of the VEXAS syndrome improves medical management of the disease and provides more effective treatment of the disease, although there is no cure currently. The diagnosis relies on the VEXAS syndrome genetic...
